Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.

Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...

Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...

Company has Deloitte Haskins & Sells LLP as its auditors. As on 31-12-2024, the company has a total of 100.62 Crore shares outstanding.Cadila Healthcare Share Price Today is Rs. 977.20. On previous ...

Zydus Lifesciences announced that the USFDA granted Orphan Drug Designation to Usnoflast, a novel oral NLRP3 inhibitor, for ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...

Zydus Life share rose after it received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral ...

This complaint was first surfaced by Law.com Radar, ALM's source for immediate alerting on just-filed cases in state and federal courts. Law.com Radar now offers state court coverage nationwide. Sign ...

Nomura cited higher contribution from diabetes drug Sitaglitptin, which offers a market size of around $300-400 million to be the biggest factor in Zydus Life's rating upgrade.

Zydus Pharmaceuticals USA Inc President & CEO Punit Patel said the relationship is a strong validation of Zydus' strategic investments in the new drug applications portfolio.

Blue Cross Blue Shield (BCBS) has the best overall health insurance plans. They're well-rated and widely available through HealthCare.gov or your state marketplace. Health insurance costs can get very ...

The U.S. pays more for prescription medicines than any other country, and incoming President Donald Trump has vowed to lower drug costs by focusing on middlemen in the U.S. healthcare system.